stockrowNurix Therapeutics, Inc.
NRIX Healthcare Biotechnology
Nurix Therapeutics, Inc.’s revenue for fiscal 2025 (year ended November 2025) was $84.0 million, up 54.0% from fiscal 2024.
- Revenue
- +8,426.3%
- EPS
- +578.6%
- Free cash flow
- +1,122.1%
Quarter to August 2026, against a year earlier
Follow NRIX
Alert me
Nurix Therapeutics, Inc. (NRIX) EV/Sales
As of 6 November 2026, Nurix Therapeutics, Inc. (NRIX) trades at a EV/Sales of 0.9×. Over the past ten years it has ranged from −0.4× (October 2023) to 74.1× (March 2021); the current reading is higher than 3% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.4× | (31.94%) |
| FY2024 | 15.3× | 2,247.40% |
| FY2023 | 0.7× | (91.43%) |
| FY2022 | 7.6× | (76.00%) |
| FY2021 | 31.6× | 45.63% |
| FY2020 | 21.7× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Aug 2026 | 2.6× | (93.57%) |
| May 2026 | 40.5× | 142.22% |
| Feb 2026 | 16.7× | 60.83% |
| Nov 2025 | 10.4× | 157.37% |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BRVE Braveheart Bio, Inc. compare | n/m |
| KLRA Kailera Therapeutics, Inc. compare | n/m |
| NRIX Nurix Therapeutics, Inc. | 0.9× |
| NVAX Novavax, Inc. compare | 3.3× |
| NTLA Intellia Therapeutics, Inc. compare | 20.9× |
| GENB Generate Biomedicines, Inc. compare | 37.2× |
| SLS SELLAS Life Sciences Group, Inc. compare | 136× |
| ABSI Absci Corporation compare | 896× |
| LYCA Lycia Therapeutics Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)